+441518081136Study of outcome and Apolipoproteins in Dementia (STOP-Dementia)
13th International Conference on Alzheimers Disease and Dementia
November 25-26, 2019 | Frankfurt, Germany
Ryo Ohtania
National Hospital Organization Kyoto Medical Center, Japan
Scientific Tracks Abstracts : J Psychol Cognition
Abstract:
Background: Amyloid-βclearance is important for damage
prevention in Alzheimer’s disease. High-density lipoprotein
(HDL) containing apolipoprotein A-I is associated with the
pathogenesis of Alzheimer’s disease (AD). HDL particle
size is modified in the presence of pathological conditions,
while the significance of the HDL particle size remains
controversial.
Objective: The aim of this study was to investigate the HDL
lipoprotein subclasses in mild cognitive impairment (MCI)
and AD.
Methods: This cross-sectional study included 20 AD
patients, 17 MCI patients, and 17 age-matched controls
without cognitive impairment, selected from the database
of the Study of Outcome and Apolipoproteins in Dementia
(STOP-Dementia) registry. The diagnoses of AD and MCI
were performed by expert neurologists according to the
Diagnostic and Statistical Manual of Mental Disorders-Fifth
Edition criteria. Serum HDL subclasses were measured
by electrophoretic separation of lipoproteins using the
Lipoprint System. The neutrophil-lymphocyte ratio (NLR),
a marker of inflammation, was calculated by dividing the
neutrophil count by the lymphocyte count.
Results: Small-sized HDL particle levels in the MCI group
were significantly higher than in the control group, although
there was no difference in serum HDL-cholesterol levels
between MCI and control groups. NLR in the MCI group
was higher than in the control group, but this difference
was non-significant (P = 0.09). There was no difference in
HDL subclasses or NLR between the AD and control groups.
Conclusion: These findings suggest that HDL subclasses
might be associated with the development of MCI. This
trial was registered with UMIN as 000019992.
Biography:
Ryo Ohtani has completed his PhD at the age of 38 years from Kyoto University, Japan. He is the director of National Hospital Organization Kyoto Medical Center, Japan. Currently, he is working as Neurologist in National Hospital Organization Kyoto Medical Center, JAPAN. He has 28 publications that have been cited.
E-mail: ryoohtani@gmail.com
PDF HTML